| Income Statement | 2025-09-30 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total other income, net | 2,652 | 4,730 | 3,653 | |
| Loss before income taxes | - | -19,122 | -22,979 | |
| Net loss | -15,849 | -19,122 | -22,979 | |
| Unrealized gains (losses) on marketable securities | 68 | 698 | 159 | |
| Total other comprehensive gain (loss) | 68 | 698 | 159 | |
| Total comprehensive loss | -15,781 | -18,424 | -22,820 | |
| Net loss per share attributable to common stockholdersbasic (in dollars per share) | -0.25 | -0.31 | -0.45 | |
| Net loss per share attributable to common stockholdersdiluted (in dollars per share) | -0.25 | -0.31 | -0.45 | |
| Weighted average common shares outstandingbasic (in shares) | 63,029,293 | 62,602,848 | 51,580,310 | |
| Weighted average common shares outstandingdiluted (in shares) | 63,029,293 | 62,602,848 | 51,580,310 | |
Foghorn Therapeutics Inc. (FHTX)
Foghorn Therapeutics Inc. (FHTX)